Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
14 pending office actions • 12 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
The Jackson Laboratory has 14 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 14 distinct examiners and 12 distinct art units, showing broad examiner distribution and a smaller degree of concentration within technical groups.
HICKS, SHIRLEY D. is the busiest examiner, with 1 pending matter. Because each pending action is associated with a distinct examiner, centralized oversight should focus on coordinating portfolio themes while preserving application-specific prosecution strategies.
The profile suggests that recurring issues, if identified, are more likely to arise from technology or art-unit context than from a dominant examiner relationship. Counsel can use art-unit grouping to organize prior-art review and claim-development decisions.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (21%) |
| §103 only | 2 (14%) |
| §102 only | 1 (7%) |
| Double-patenting + other | 1 (7%) |
| Multi-statute (no §101) | 7 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HICKS, SHIRLEY D. | 1 | 60.3% | +51.2% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| FISHBACK, ASHLEY LAUREN | 1 | 80.0% | +22.1% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
| PENG, BO JOSEPH | 1 | 69.5% | +13.6% |
| JOHANNSEN, DIANA B | 1 | 53.2% | +42.8% |
| BAUSCH, SARAE L | 1 | 29.7% | +45.0% |
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
| MOHAMMED, SHAHDEEP | 1 | 51.7% | +56.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015043 | TRANSGENIC MOUSE MODEL EXPRESSING HUMAN HLA-A201 RESTRICTION GENE | WILSON, MICHAEL C | 25d overdue |
| 17275653 | METHOD AND APPARATUS FOR DETECTING COPY NUMBER VARIATIONS IN A GENOME | ROSSI, VY BUI | 4d overdue |
| 17813561 | METHOD OF SELECTING A TREATMENT FOR AN MS PATIENT | HOEKSTRA, JEFFREY GERBEN | 72d |
| 18865074 | IMPLANTABLE DATA LOGGER ANCHORING DEVICES | FISHBACK, ASHLEY LAUREN | — |
| 18723361 | HUMANIZED MOUSE MODELS | BARRON, SEAN C | — |
| 18563207 | RADIOSENSITIZING COMPOSITIONS AND METHODS | PENG, BO JOSEPH | — |
| 18280198 | MULTIPLEX RNA TARGETING | JOHANNSEN, DIANA B | — |
| 18001841 | Small Deletion Signatures | BAUSCH, SARAE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18874860 | SYSTEMS AND METHODS FOR IDENTIFYING CROSS-SPECIES GENE AND GENE VARIANT RELATIONSHIPS | HICKS, SHIRLEY D. | 12d |
| 18007429 | Automated Phenotyping of Behavior | MOHAMMED, SHAHDEEP | 14d |
| 18972072 | HUMANIZED MOUSE MODELS FOR ASSESSING IMMUNE CELL THERAPY | LEONARD, ARTHUR S | — |
| 18865074 | IMPLANTABLE DATA LOGGER ANCHORING DEVICES | FISHBACK, ASHLEY LAUREN | — |
| 18723361 | HUMANIZED MOUSE MODELS | BARRON, SEAN C | — |
| 18563207 | RADIOSENSITIZING COMPOSITIONS AND METHODS | PENG, BO JOSEPH | — |
| 18280198 | MULTIPLEX RNA TARGETING | JOHANNSEN, DIANA B | — |
| 18001841 | Small Deletion Signatures | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 3797 | 2 |
| 2168 | 1 |
| 3771 | 1 |
| 1653 | 1 |
| 1682 | 1 |
| 1699 | 1 |
| 1683 | 1 |
| 1632 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18874860 | SYSTEMS AND METHODS FOR IDENTIFYING CROSS-SPECIES GENE AND GENE VARIANT RELATIONSHIPS | HICKS, SHIRLEY D. | 2168 | §102 | Final Rejection | 12d | Pending | Dec 13, 2024 |
| 18972072 | HUMANIZED MOUSE MODELS FOR ASSESSING IMMUNE CELL THERAPY | LEONARD, ARTHUR S | 1631 | §103DP | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18865074 | IMPLANTABLE DATA LOGGER ANCHORING DEVICES | FISHBACK, ASHLEY LAUREN | 3771 | §102§112 | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18723361 | HUMANIZED MOUSE MODELS | BARRON, SEAN C | 1653 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18563207 | RADIOSENSITIZING COMPOSITIONS AND METHODS | PENG, BO JOSEPH | 3797 | §103§112 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18280198 | MULTIPLEX RNA TARGETING | JOHANNSEN, DIANA B | 1682 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18001841 | Small Deletion Signatures | BAUSCH, SARAE L | 1699 | §101§102§112 | Non-Final OA | — | Pending | Jul 24, 2023 |
| 18272260 | PROGNOSTIC METHODS FOR PLATINUM-BASED CHEMOTHERAPEUTICS | POHNERT, STEVEN C | 1683 | §101§103§112 | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18265521 | INFECTIOUS DISEASE MOUSE MODELS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Final Rejection | — | Pending | Jun 06, 2023 |
| 18007429 | Automated Phenotyping of Behavior | MOHAMMED, SHAHDEEP | 3797 | §103 | Non-Final OA | 14d | Pending | Jan 30, 2023 |
| 18015042 | TRANSGENIC MOUSE MODELS SUPPORTING HUMAN INNATE IMMUNE FUNCTION | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | — | Pending | Jan 06, 2023 |
| 18015043 | TRANSGENIC MOUSE MODEL EXPRESSING HUMAN HLA-A201 RESTRICTION GENE | WILSON, MICHAEL C | 1638 | §103§112 | Final Rejection | 25d overdue | Pending | Jan 06, 2023 |
| 17813561 | METHOD OF SELECTING A TREATMENT FOR AN MS PATIENT | HOEKSTRA, JEFFREY GERBEN | 3791 | §102§112 | Final Rejection | 72d | Pending | Jul 19, 2022 |
| 17275653 | METHOD AND APPARATUS FOR DETECTING COPY NUMBER VARIATIONS IN A GENOME | ROSSI, VY BUI | 1685 | §101§103 | Final Rejection | 4d overdue | Pending | Mar 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Jackson Laboratory has 14 pending office actions as of October 2026, spread across 12 art units and 14 examiners.
Shirley D. Hicks has the most, with 1 of The Jackson Laboratory's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
